UK markets closed

Synmosa Biopharma Corporation (4114.TWO)

Taipei Exchange - Taipei Exchange Delayed price. Currency in TWD
Add to watchlist
39.10+0.35 (+0.90%)
At close: 01:30PM CST
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Total revenue
4,048,464
5,140,495
4,386,364
3,234,960
3,038,286
Cost of revenue
2,384,801
3,020,566
2,559,720
1,949,592
1,905,218
Gross profit
1,663,663
2,119,929
1,826,644
1,285,368
1,133,068
Operating expenses
Research development
206,318
210,905
215,281
214,373
159,526
Selling general and administrative
1,075,770
1,286,622
1,148,395
883,584
817,243
Total operating expenses
1,285,284
1,499,593
1,371,621
1,100,166
1,013,558
Operating income or loss
378,379
620,336
455,023
185,202
119,510
Interest expense
54,911
67,257
59,580
51,972
52,822
Income before tax
641,123
601,558
725,011
153,886
497,645
Income tax expense
89,076
196,389
106,126
37,811
23,042
Income from continuing operations
552,047
405,169
618,885
116,075
474,603
Net income
735,290
594,832
799,091
303,860
638,112
Net income available to common shareholders
735,290
594,832
799,091
303,860
638,112
Basic EPS
1.59
-
2.25
0.84
1.99
Diluted EPS
1.59
-
2.24
0.83
1.99
Basic average shares
365,605
-
355,152
361,593
320,261
Diluted average shares
366,677
-
356,737
362,792
321,831